Special Reports

December 2013

Colorectal Cancer in China

Report Authors
Youling Guo, Ph.D.
Prachi Vora, M.P.H.
  • Pages:105
  • Tables:26
  • Figures:46
  • Citations:N/A
  • Drugs:14
  • Interviews:90 Surveys/8 Interviews

Introduction:

China has one of the most rapidly growing pharmaceutical markets in the world, as well as a vast, rapidly expanding prevalent population of colorectal cancer (CRC) patients. Combined with increasing access to medical care and a burgeoning middle class with growing economic clout, these factors promise fast growth and significant opportunity for multinational pharmaceutical companies.

Questions Answered in This Report:

  *   China is the most populous country in the world, with more than 1.3 billion citizens in 2012. The risk of developing CRC is increasing rapidly in China because of the aging population and the influence of urbanization. How will the number of incident cases of CRC change from 2012 to 2022? How will the drug-treatment rates change in urban and rural regions of China from 2012 to 2017?

  *   The prescribing patterns of Chinese physicians, like those of their counterparts in the United States and Europe, are most influenced by a drug’s safety and efficacy profile. However, cost is much more of a constraint in CRC treatment in China than in Western countries due to the low per capita income level of Chinese people. How do these factors drive Chinese physicians’ prescribing habits? How do physicians choose between branded Western drugs and Chinese-manufactured equivalents for the treatment of CRC? What are Chinese physicians’ opinions of and experiences with targeted therapies? How does biomarker testing guide personalized treatment of CRC in China?

  *   The Chinese CRC market is growing rapidly, recording strong annual gains in sales. What is the size of the CRC market in 2012? How large will the Chinese CRC market be in 2017? How do branded Western drugs fare against Chinese competitors? Which drugs will dominate the Chinese CRC market in 2017? What emerging therapies will enter the CRC therapeutic market during the 2012-2017 period?

Scope:

Market Covered: China.

Primary research: A total of 90 oncologists surveyed in Beijing, Shanghai, and Guangzhou. Separate in-depth interviews with 8 medical experts.

Epidemiology: Prevalence of CRC: total diagnosed incident cases in urban and rural China. Ten-year epidemiology forecasts through 2022.

Market forecast features: Our analysis evaluates the size of the population receiving drug treatment. We include a detailed forecast for CRC drug classes and leading brands for 2012-2017 using a combination of historical trend analysis and an epidemiology-based, bottom-up market model.


Search Reports

Mentioned in this report:

  • - Alchemia
  • - Amgen
  • - Bayer
  • - Biothera
  • - Eli Lilly
  • - ImClone Systems
  • - Jiangsu Hengrui
  • - Light Sciences Oncology
  • - Merck KGaA
  • - Nanjing Chia Tai Tianqing
  • - Pfizer
  • - Roche
  • - Sanofi
  • - SD. Simcere Medgenn
  • - Taiho
  • - Takeda
  • - Vaccinogen
Decision Resources Group brands include: